



Registered Office Address - K. No. 72/5, Village Muradpura, Depalpur, Indore, Madhya Pradesh - 453001

Date: December 26, 2025

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai – 400051, Maharashtra, India.

NSE Symbol: ZENITHDRUG; ISIN- INE0QWN01013

Subject: Clarification on News Item Published in Dainik Bhaskar dated 24/12/2025

Regulation: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sir/Madam,

This is with reference to the news item published in the newspaper "*Dainik Bhaskar*" dated 24 December 2025, wherein it was reported that certain medicine samples were declared as *Not of Standard Quality (NSQ)* by Government authorities and the name of **Zenith Drugs Limited** was mentioned along with other companies.

In this regard, the Company would like to clarify that **as on date, it has not received any communication, notice, report, or intimation from any Government authority** with respect to the said matter. **In the absence of any official confirmation, the Company is not in a position to comment on the veracity of the said news item at this stage.**

Without prejudice to the above, Zenith Drugs Limited has been engaged in the manufacturing and supply of quality medicines since 2001 and follows robust quality systems. Each instance of NSQ, wherever reported, is thoroughly investigated and appropriate **CAPA** is implemented. The Company has consistently submitted responses to **CDSCO** and other regulatory authorities.

CDSCO and the State FDA have jointly audited and inspected the Company's facilities and products from time to time, including inspections related to cough syrup manufacturing and a **Risk-Based Inspection (RBI)**. The Company has received clearance for all observations. Till date, no product failure or adverse drug reaction has been identified in the Company's systems or control samples.

The newspaper article referred to multiple companies and failed samples; however, **no specific details or number of NSQs attributable to Zenith Drugs Limited were mentioned.**

In view of the above, the Company believes that the said news item **does not have any adverse impact on its operations or financial position**. The Company remains committed to maintaining high quality standards and regulatory compliance.

Kindly take the above clarification on record.

Thank you.

For Zenith Drugs Limited

Sakshi Bhawsar
Company Secretary & Compliance Officer